Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Johnson & Johnson reports 48-week Tremfya fistula-remission data
The company says new data show Tremfya (guselkumab) delivered durable fistula remission through 48 weeks in Crohn’s disease patients with perianal fistula, describing it as the only IL-23 to do so.
Johnson & Johnson reports TREMFYA fistula remission data
New data show TREMFYA delivered durable fistula remission through 48 weeks in Crohn’s disease patients with perianal fistula; the announcement describes it as the only IL-23 to do so.
Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
For best results when printing this announcement, please click on link below: Johnson & Johnson reports Q3 2026 results, raises 2026 guidance 2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1% 2026 Third-Quarter earnings per share (